{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the 95% confidence interval was not estimable due to insufficient number of participants with events at the tail of the Kaplan-Meier curve.","groupId":"OG000","lowerLimit":"3.4","upperLimit":"NA","value":"18.9"},{"comment":"The median and upper bound of the 95% confidence interval was not estimable due to insufficient number of participants with events at the tail of the Kaplan-Meier curve.","groupId":"OG001","lowerLimit":"5.5","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Overall survival is defined as the interval from the date of the first dose until the recorded date of death due to any cause. Overall survival was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).","id":"OG000","title":"Melanoma Cohort"},{"description":"Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.","id":"OG001","title":"Tissue Agnostic Cohort"}],"paramType":"MEDIAN","populationDescription":"Efficacy Analysis Set comprises of all participants who received at least one dose of study drug and have measurable disease as determined by the Investigator at baseline.","reportingStatus":"POSTED","timeFrame":"Up to 23 months","title":"Duration of Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}